Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Prostate Cancer (NEPC)”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164794
What this trial is testing

Memantine Hydrochloride in Prostate Cancer Patients

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostate CancerNeuroendocrine Prostate Cancer (NEPC)
Bin Xu 15
Early research (Phase 1)Ended earlyNCT02875223
What this trial is testing

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinNeoplasms
Celgene 75
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Early research (Phase 1)Ended earlyNCT02963051
What this trial is testing

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Daniel George, MD 9
Early research (Phase 1)Active Not RecruitingNCT06379217
What this trial is testing

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Who this might be right for
Metastatic Neuroendocrine Prostate Cancer
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Early research (Phase 1)Looking for participantsNCT07006727
What this trial is testing

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Who this might be right for
Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals 116
Testing effectiveness (Phase 2)Study completedNCT03179410
What this trial is testing

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Who this might be right for
Prostate Cancer
Andrew J. Armstrong, MD 15
Early research (Phase 1)Not Yet RecruitingNCT07488923
What this trial is testing

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Who this might be right for
Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)+1 more
Moonlight Bio, Inc 110